The 37 references in paper A. Yakovlev Yu, N. Gushchina N., A. Niyazmatov A., R. Zatsev M, E. Golubtsova Yu, M. Ryabikova A., А. Яковлев Ю., Н. Гущина Н., А. Ниязматов А., Р. Зайцев М, Е. Голубцова Ю., М. Рябикова А. (2013) “Ранняя оценка эффективности антибактериальной терапии нозокомиальной пневмонии путем количественного определения липополисахарида // Early Evaluation of the Efficiency of Antibiotic Therapy for Nosocomial Pneumonia by Quantifying Lipopolysaccharide” / spz:neicon:reanimatology:y:2013:i:6:p:45

1
American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med.2005; 171 (4): 388–416. PMID: 15699079
(check this in PDF content)
2
Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P.Nosocomial infections in medical ICUs in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 1999; 27 (5): 887–892. PMID: 10362409
(check this in PDF content)
3
Smelaya T.V., Salnikova L.E., Moroz V.V., Golubev A.M., Zarzhetsky Yu.V., Rubanovich A.V.Genetichesky polimorfizm i chastota razvitiya oslozhnenii pri pnevmonii razlichnogo geneza. [Genetic polymorphism and the rate of development of complications in pneumonia of varying genesis]. Obshchaya Reanimatologiya. 2011; 7 (2): 10—17. [In Russ.]
(check this in PDF content)
4
Khubutiya M.Sh., Shabanov A.K., Chernenkaya T.V., Godkov M.A., Dorfman A.G. Infektsionnye legochnye oslozhneniya v reanimatsii i intensivnoi terapii u postradavshikh s sochetannoi travmoi. [Infectious pulmonary complications in intensive care unit victims with concomitant injury]. Obshchaya Reanimatologiya.2011; 7 (4): 24—27. [In Russ.]
(check this in PDF content)
5
Depuydt P., Myny D., Blot S.Nosocomial pneumonia: aetiology, diagnosis and treatment. Curr. Opin. Pulm. Med.2006; 12 (3): 192—197. PMID: 16582674
(check this in PDF content)
6
Iregui M., Ward S., Sherman G., Fraser V.J., Kollef M.H.Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest.2002; 122 (1): 262–268. http://dx.doi.org/10.1378/chest.122.1.262. PMID: 12114368
(check this in PDF content)
7
Chuchalin A.G., Gelfand B.R. (red.).Nozokomialnaya pnevmoniya u vzroslykh. Rossiiskie natsionalnye rekomendatsii. [Nosocomial pneumonia in adults. Russian national guidelines]. Moscow: Borges; 2009. [In Russ.]
(check this in PDF content)
8
Beloborodov V.B.Antibakterialnaya terapiya pnevmonii, svyazannoi s iskusstvennoi ventilyatsiei legkikh: put ot natsionalnykh rekomendatsii do primeneniya v otdelenii. [Antibacterial therapy for mechanical ventilation-associated pneumonia: A path from national guidelines to their use in the unit]. Infektsii v Khirurgii.2011; 9 (2): 66—72. [In Russ.]
(check this in PDF content)
9
Luna C.M., Aruj P., Niederman M.S., Garzo ́n J., Violi D., Prignoni A., Ríos F., Baquero S., Gando S.; Grupo Argentino de Estudio de la Neumonнa Asociada al Respirador group. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur. Respir. J.2006; 27 (1): 158–164. PMID: 16387949
(check this in PDF content)
10
Wood G.C., Boucher B.A.Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy.2000; 20 (2): 166—181. http://dx.doi.org/10.1592/phco.20.3.166.34783. PMID: 10678295
(check this in PDF content)
11
Moss R.B.Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest.2002; 121 (1): 55—63. http://dx.doi.org/10. 1378/chest.121.1.55. PMID: 11796432
(check this in PDF content)
12
Cheer S.M., Waugh J., Noble S.Inhaled tobramycin (TOBI): A review of its use in the management of Pseudomonas aeruginosainfections in patients with cystic fibrosis. Drugs.2003; 63 (22): 2501—2520. http://dx.doi.org/10.2165/00003495-200363220-00015. PMID: 14609360
(check this in PDF content)
13
Carcas A.J., García-Satue ́J.L., Zapater P., Frías-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther.1999; 65 (3): 245–250. http://dx.doi.org/10.1016/ S0009-9236(99)70103-7. PMID: 10096256
(check this in PDF content)
14
Goldstein I., Wallet F., Nicolas-Robin A., Ferrari F., Marquette C.-H., Rouby J.-J.Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med.2002; 166 (10): 1375–1381. PMID: 12406838
(check this in PDF content)
15
Makhoul I.R., Merzbach D., Lichtig C., Berant M.Antibiotic treatment of experimental Pseudomonas aeruginosapneumonia in guinea pigs: comparison of aerosol and systemic administration. J. Infect. Dis.1993; 168 (5): 1296–1299. PMID: 8228367
(check this in PDF content)
16
Kahler D.A., Schowengerdt K.O., Fricker F.J., Mansfield M., Visner G.A., Faro A.Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy.2003; 23 (4): 543–545. http://dx.doi.org/10.1592/phco.23.4.543.32122. PMID: 12680485
(check this in PDF content)
17
Moroz V.V., Kuzovlev A.N., Polovnikov S.G., Stets V.V., Varvarin V.V. Ingalyatsionnyi tobramitsin v lechenii tyachelykh nozokomialnykh pnevmonii. [Inhaled tobramycin in the treatment of severe nosocomial pneumonias]. Obshchaya Reanimatologiya. 2012; 8 (2): 5—9. [In Russ.]
(check this in PDF content)
18
Avdeyev S.N., Karchevskaya N.A., Chuchalin A.G.Opyt ispolzovaniya ingalyatsionnogo tobramitsina pri nozokomialnoi pnevmonii. [Experience with inhaled tobramycin in nosocomial pneumonia]. Lechebnoe Delo.2009; 2: 80—88. [In Russ.]
(check this in PDF content)
19
Le Conte P., Potel G., Clementi E., Legras A., Villers D., Bironneau E., Cousson J., Baron D.Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse Med.2000; 29 (2): 76–78. PMID: 10682031
(check this in PDF content)
20
Hallal A., Cohn S.M., Namias N., Habib F., Baracco G., Manning R.J., Crookes B., Schulman C.I.Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg. Infect. (Larchmt). 2007; 8 (1): 73—82. http://dx.doi.org/10.1089/sur.2006.051. PMID: 17381399
(check this in PDF content)
21
Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A.Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2009; 28 (3): 253—259. http://dx.doi.org/10.1007/s10096-008-0620-5. PMID: 18752007
(check this in PDF content)
22
Mohr A.M., Sifri Z.C., Horng H.S., Sadek R., Savetamal A., Hauser C.J., Livingston D.H.Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg. Infect. (Larchmt).2007; 8 (3): 349—357. http://dx.doi.org/10.1089/ sur.2006.041. PMID: 17635058
(check this in PDF content)
23
McCall C.Y., Spruill W.J., Wade W.E.The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonia. Ther. Drug Monit.1989; 11 (6): 692–695. PMID: 2595751
(check this in PDF content)
24
Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D., Clementi E., Gonzalez J., Jusserand D., Asfar P., Perrin D., Fieux F., Aubas S.; PneumA Trial Group.Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA. 2003; 290 (19): 2588–2598. http://dx.doi.org/10.1001/jama.290.19.2588. PMID: 14625336
(check this in PDF content)
25
Beloborodov V.B.Prakticheskie rekomendatsii po diagnostike i lecheniyu nozokomialnoi pnevmonii: chto novogo? [Practical guidelines for the diagnosis and treatment of nosocomial pneumonia: What is new?] Infektsii i Antimikrobnaya Terapiya.2005; 2: 60—66. [In Russ.]
(check this in PDF content)
26
Khairullina R.M., Mavzyutov A.R., Fazlyeva R.M., Akbasheva A.O., Kuzovkina O.Z.Sostoyanie antiendotoksinovoi zashchity pri vnebolnichnoi pnevmonii. [The antiendotoxin defense in community-acquired pneumonia]. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii. 2010; 4: 65—71. [In Russ.]
(check this in PDF content)
27
Matkevich V.A., Luzhnikov E.A., Ilyashenko K.K., Petrov S.N., Nikulina V.P., Evdokimova N.V.Vliyanie kishechnogo lavazha na razvitie pnevmonii u bolnykh s ostrymi otravleniyami psikhofarmakologicheskimi sredstvami. [Impact of intestinal lavage on the development of pneumonia in patients with acute poisonings by psychopharmacological agents]. Obshchaya Reanimatologiya. 2011; 7 (2): 20—24. [In Russ.]
(check this in PDF content)
28
Grotta M.B., Etchebere E.C., Ribeiro A.F., Romanato J., Ribeiro M.A., Ribeiro J.D. Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. J. Bras. Pneumol. 2009; 35 (1): 35—43. PMID: 19219329
(check this in PDF content)
29
Mayansky A.N.Mikrobiologiya dlya vrachei. [Microbiology for physicians]. Nizhny Novgorod: NGMA; 1999: 127. [In Russ.]
(check this in PDF content)
30
Yakovlev V.P., Yakovlev S.V., Aleksandrova I.A.Ratsionalnaya antimikrobnaya terapiya. [Rational antimicrobial therapy]. Moscow: Litterra; 2007: 783. [In Russ.]
(check this in PDF content)
31
Palmer L.B., Smaldone G.C., Simon S.R., O’Riordan T.G., Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med.1998; 26 (1): 31–39. http://dx.doi.org/10.1097/00003246-199801000-00013. PMID: 9428540
(check this in PDF content)
32
Goldstein I., Chastre J., Rouby J.J.Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents. Semin. Respir. Crit. Care Med. 2006; 27 (1): 82–91. http://dx.doi.org/10.1055/s-2006-933676. PMID: 16508884
(check this in PDF content)
33
Conrad D.J.The clinical use of aerosolized antibiotics. Clin. Pulm. Med. 2003; 10 (4): 201—220. http://dx.doi.org/10.1097/01.cpm. 0000080903.11193.e9.
(check this in PDF content)
34
Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest.2002; 122 (1): 219–226. http://dx.doi.org/ 10.1378/chest.122.1.219. PMID: 12114362
(check this in PDF content)
35
Le Conte P., Potel G., Peltier P., Horeau D., Caillon J., Juvin M.E., Kergue ́ris M.F., Bugnon D., Baron D.Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis.1993; 147 (5): 1279—1282. http://dx.doi.org/10.1164/ajrccm/147.5.1279. PMID: 8484643
(check this in PDF content)
36
Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., Vasiljev K.M., Borowitz D., Bowman C.M., Marshall B.C., Marshall S., Smith A.L.Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med.1999; 340 (1): 23–30. http://dx.doi.org/10.1056/NEJM199901073400104. PMID: 9878641
(check this in PDF content)
37
Touw D.J., Jacobs F.A., Brimicombe R.W., Heijerman H.G., Bakker W., Briemer D.D.Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother.1997; 41 (1): 184–187. PMID: 8980777 Submited 01.03.13
(check this in PDF content)